Skip to main content

Table 2 Combined results of the significant drugs returned from sscMap using the 5 Tumor-vs-Normal gene signatures as queries

From: An integrated meta-analysis approach to identifying medications with potential to alter breast cancer risk through connectivity mapping

Compound

Replicates

Mean z

p 1

z 1

p 2

z 2

p 3

z 3

p 4

z 4

p 5

z 5

budesonide

85

-7.78

2.00E-09

-6

1.20E-13

-7.41

1.70E-20

-9.28

9.60E-12

-6.81

6.00E-21

-9.39

menadione

364

-7.26

4.50E-12

-6.92

8.20E-18

-8.6

2.60E-10

-6.32

1.20E-12

-7.1

1.90E-13

-7.35

cytarabine

48

-7.09

8.70E-16

-8.04

2.00E-20

-9.26

5.90E-11

-6.55

3.30E-06

-4.65

3.80E-12

-6.95

methotrexate

10

-6.81

4.20E-11

-6.6

1.30E-18

-8.8

2.40E-09

-5.97

2.80E-09

-5.94

1.80E-11

-6.72

gemcitabine hydrochloride

107

-6.55

7.30E-12

-6.85

8.10E-20

-9.11

1.30E-10

-6.43

3.60E-06

-4.63

1.00E-08

-5.72

milnacipran

37

-6.39

1.40E-07

-5.26

5.10E-13

-7.22

7.90E-15

-7.77

2.20E-05

-4.24

1.00E-13

-7.44

sulfafurazole

34

6.26

2.60E-10

6.32

1.20E-08

5.7

6.50E-11

6.53

8.10E-05

3.94

1.60E-18

8.78

amethopterin

36

-6.24

2.20E-07

-5.19

7.10E-19

-8.87

8.00E-12

-6.84

2.20E-04

-3.69

4.30E-11

-6.59

dihomo-gamma-linolenic acid

52

6.03

3.50E-10

6.28

1.10E-06

4.88

8.80E-10

6.13

1.60E-05

4.32

1.10E-17

8.57

etoposide

35

-5.99

6.20E-08

-5.41

1.60E-20

-9.28

5.30E-07

-5.02

8.00E-07

-4.93

1.10E-07

-5.31

s1025

65

-5.97

5.80E-07

-5

1.60E-11

-6.74

1.70E-05

-4.3

3.00E-08

-5.54

1.50E-16

-8.25

auranofin

3

-5.92

2.90E-09

-5.94

2.00E-11

-6.7

1.20E-06

-4.85

1.10E-09

-6.1

1.70E-09

-6.02

topotecan hcl

23

-5.85

1.20E-09

-6.08

8.40E-11

-6.49

1.40E-06

-4.82

6.80E-07

-4.97

6.20E-12

-6.87

minoxidil

88

5.75

1.90E-09

6.01

2.40E-04

3.67

1.10E-11

6.79

1.20E-05

4.38

2.50E-15

7.92

dlotrimazole

47

-5.6

5.50E-09

-5.83

5.20E-11

-6.57

8.80E-07

-4.92

2.60E-06

-4.7

2.10E-09

-5.99

metaraminol bitartrate

10

-5.53

2.50E-09

-5.96

6.30E-06

-4.52

8.10E-16

-8.05

2.60E-05

-4.2

9.60E-07

-4.9

cefotiam hydrochloride

33

5.33

3.00E-10

6.3

7.30E-08

5.38

1.10E-06

4.88

1.90E-04

3.74

2.20E-10

6.34

azacitidine

12

-5.16

5.00E-05

-4.05

6.80E-11

-6.52

2.90E-07

-5.13

2.30E-07

-5.18

8.70E-07

-4.92

sulfacetamide

90

5.11

3.70E-06

4.63

3.50E-08

5.52

1.90E-07

5.21

2.10E-04

3.71

8.10E-11

6.5

9-cis retinoic acid

22

5.11

9.80E-07

4.9

7.80E-09

5.77

6.80E-08

5.4

1.60E-04

3.77

1.00E-08

5.73

teniposide

347

-5.01

8.30E-06

-4.46

2.50E-15

-7.91

1.60E-04

-3.77

4.70E-06

-4.58

1.30E-05

-4.36

aminolevulinic acid

44

-4.98

5.40E-05

-4.04

2.60E-10

-6.32

5.00E-05

-4.05

7.30E-04

-3.38

1.10E-12

-7.12

fluvastatin

107

-4.93

1.30E-04

-3.82

1.20E-10

-6.44

1.40E-06

-4.82

1.10E-05

-4.4

2.70E-07

-5.14

doxorubicin

159

-4.76

7.10E-08

-5.39

2.50E-09

-5.96

4.80E-04

-3.49

7.70E-05

-3.95

5.90E-07

-4.99

mometasone furoate

29

-4.74

1.40E-05

-4.35

3.00E-07

-5.12

4.80E-05

-4.06

1.90E-05

-4.27

4.00E-09

-5.88

desipramine hydrochloride

57

-4.61

1.60E-05

-4.32

3.00E-05

-4.17

8.30E-06

-4.46

9.30E-06

-4.43

1.60E-08

-5.65

doxylamine succinate

57

4.59

9.10E-07

4.91

1.30E-04

3.83

1.50E-05

4.33

2.30E-05

4.24

1.50E-08

5.66

sertraline hydrochloride

46

-4.55

9.60E-05

-3.9

2.00E-05

-4.27

1.70E-07

-5.23

2.20E-04

-3.69

1.60E-08

-5.65

diloxanide furoate

58

-4.52

4.80E-07

-5.03

3.50E-05

-4.14

9.80E-07

-4.9

3.80E-05

-4.12

1.00E-05

-4.41

chlorambucil

166

-4.46

8.60E-05

-3.93

4.50E-09

-5.87

1.80E-06

-4.77

1.50E-05

-4.33

7.10E-04

-3.39

2-chloro-2’-deoxyadenosine

49

-4.43

1.50E-05

-4.32

7.70E-08

-5.37

9.40E-06

-4.43

5.60E-04

-3.45

4.60E-06

-4.58

bacitracin

11

-4.11

8.10E-05

-3.94

9.30E-08

-5.34

4.00E-04

-3.54

1.30E-04

-3.82

8.70E-05

-3.92

s1222

66

-3.82

3.80E-04

-3.55

2.20E-06

-4.73

2.80E-04

-3.63

4.60E-04

-3.51

2.40E-04

-3.68

  1. This table lists only those drugs that are significant for all these 5 signatures